
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics is a clinical-stage biopharmaceutical company, with a focus on developing important therapies for people living with cancer. Investors can look forward to additional data from ficerafusp alfa in 1L HPV- HNSCC and in 3L+ mCRC, as well as other upcoming catalysts such as presentation of long-term follow-up data from Phase 1b study of ficerafusp alfa + Keytruda in 1L R/M HPV-negative HNSCC and data from Phase 1b expansion cohort in 2H26. Additionally, Bicara's CRC program has the potential to recruit approximately 40 patients across two cohorts and remains a signal-seeking effort. However, in our bullish case, we project the company's stock to achieve increased prices, reflecting the potential success of their innovative treatments.
Bears say
Bicara Therapeutics is a Boston-based biotech company focused on developing bifunctional antibody therapies for cancer treatment. Despite the potential for success with ficerafusp alfa, there are significant risks due to its early stage in clinical trials and competition in the oncology market. Despite promising financials and expected milestones, investors should approach with caution due to the inherent risks involved in biotech companies and an already saturated market.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares